Literature DB >> 8695816

Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes.

S D Raynaud1, M Baens, J Grosgeorge, K Rodgers, C D Reid, M Dainton, M Dyer, J G Fuzibet, N Gratecos, B Taillan, N Ayraud, P Marynen.   

Abstract

We have identified a new recurrent reciprocal translocation between chromosome 3 and 12 with breakpoints at bands 3q26 and 12p13, t(3;12)(q26;p13) in the malignant cells from five patients with acute transformation of myelodysplastic syndrome or blast crisis of chronic myelogenous leukemia. t(3;12)(q26;p13) appears as a rare but nonrandom event present in various myeloid leukemia subtypes, which is frequently associated with dysplasia of megakaryocytes, multilineage involvement, short duration of any blastic phase, and a very poor prognosis. Here, we report the molecular cytogenetic analysis of the t(3;12). Fluorescence in situ hybridization results indicate that the 3q26 breakpoints are quite heterogeneous and occur 5' of MDS1, 3' of EVI1, or between MDS1 and EVI1. Our results are very similar to those observed in other 3q26 rearrangements in which breakpoints were shown to occur over considerable distances 5' and 3' of EVI1. Fluorescence in situ hybridization investigations proved that, in three myelodysplastic syndrome cases with t(3;12)(q26;p13), the 12p 13 breakpoint occurred within the TEL gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695816

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Molecular pathogenesis of MDS.

Authors:  Hisamaru Hirai
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 2.  Leukemogenesis of the EVI1/MEL1 gene family.

Authors:  Kazuhiro Morishita
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

3.  Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities.

Authors:  Arash Ronaghy; Shimin Hu; Zhenya Tang; Wei Wang; Guilin Tang; Sanam Loghavi; Shaoying Li; Beenu Thakral; L Jeffrey Medeiros; Tariq Muzzafar
Journal:  Mod Pathol       Date:  2020-10-27       Impact factor: 7.842

Review 4.  Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.

Authors:  Fabian Lang; Lydia Wunderle; Heike Pfeifer; Susanne Schnittger; Gesine Bug; Oliver G Ottmann
Journal:  Am J Case Rep       Date:  2017-10-16

Review 5.  EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.

Authors:  Christine Birdwell; Warren Fiskus; Tapan M Kadia; Courtney D DiNardo; Christopher P Mill; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2021-03-22       Impact factor: 11.037

6.  A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy.

Authors:  Ayda Bennour; Ikram Tabka; Yosra Ben Youssef; Zahra Kmeira; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Cancer Biol Med       Date:  2013-03       Impact factor: 4.248

Review 7.  The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers.

Authors:  Bernard Friedenson
Journal:  BMC Cancer       Date:  2007-08-06       Impact factor: 4.430

8.  De novo acute myeloid leukemia subtype-M4 with initial trisomy 8 and later acquired t(3;12)(q26;p12) leading to ETV6/MDS1/EVI1 fusion transcript expression: A case report.

Authors:  Walid Al Achkar; Abdulmunim Aljapawe; Thomas Liehr; Abdulsamad Wafa
Journal:  Oncol Lett       Date:  2014-01-08       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.